CluePoints Introduces Risk-Based Monitoring Software for Operational Data Analysis at DIA 2015
Cambridge, MA - CluePoints, a leading provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, today introduced software to enable analyses of operational data using a risk-based monitoring approach at DIA 2015. The new software includes Key Risk Indicators (KRIs) that perfectly complement the statistical analysis of clinical data. This KRI+ approach allows sponsors and CROs to set their own subjective threshold levels, while also statistically examining data objectively to show how a single site's KRIs can be judged against results across all other sites. CluePoints will demonstrate its latest software offering on booth #1511 at the DIA 2015 51st Annual Meeting in Washington, DC.
CluePoints' award-winning SMART™ Engine lies at the heart of the solution and has been designed to offer independent and objective interrogation of clinical data, leaving no stone unturned in assessing data quality and integrity. The enhancement of the engine with the KRI+ approach provides users with the powers of statistical analysis alongside their own triggers for action across key operational variables. This means that more frequent operational analyses can be conducted, and, when coupled with exhaustive interrogation of all clinical data, the software ensures that sponsors and CROs are able to de-risk studies and improve data quality and integrity using an automated approach. Additionally, the new software will soon support an online, customizable version of the Transcelerate-recommended Risk-Assessment Categorization Tool (RACT), allowing the CluePoints monitoring platform to provide upfront study/site risk assessment.
"With our latest software release we wanted to enable our customers to incorporate objective statistical analysis, while also allowing users to assess key operational variables to provide the most meticulous interrogation of all clinical data", comments FranÒ«ois Torche, CEO, CluePoints. "This is our latest advancement in helping our customers move towards 0% SDV and 100% data quality oversight, enabling clinical workflows to be streamlined and resources to be more effectively managed by focusing attention on the sites and data that really matter."
At the DIA 2015 Annual Meeting CluePoints' data quality thought leaders will present two interactive sessions. Delegates can learn about 'Ensuring Data Quality and Detecting Potential Fraud' on Tuesday, June 16 at 8:00-9:30am (#209, Track 07A) and 'Integrating Central Statistical Monitoring in a Quality by Design Approach for Clinical Trials' on Wednesday, June 17 at 3:30-5:00pm (#391 Track 15).
For further information on CluePoints or to request a demo of the new software, please visit booth #1511 at the DIA 2015 Annual Meeting or www.CluePoints.com
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
